OBJECTIVE: To describe the management of dyslipidaemia in patients with high risk of cardiovascular disease (CVD) and patients with a history of CVD identified by screening for diabetes in general practice in Denmark, concentrating on prescription of lipid-lowering drugs. Moreover, to analyse predicting factors for starting lipid-lowering drugs related to patient and general practice characteristics. DESIGN: Population-based cross-sectional study with follow-up. SETTING: A total of 139 general practices from three of five Danish regions, totalling 216 GPs. SUBJECTS: The study population comprised 4986 patients with a high risk of CVD and dyslipidaemia and 764 patients with a history of CVD and dyslipidaemia out of a population of 16 572 patients who completed screening for diabetes but were cleared for diabetes in the ADDITION study. RESULTS: Of patients with a high risk of CVD and dyslipidaemia not receiving lipid-lowering drugs at the time of screening (n = 4823), 20% started lipid-lowering therapy within the follow-up period (median 2.1 years). This percentage was 45% (n = 536) for patients with CVD and dyslipidaemia (median follow-up period 1.6 years). Age over 50, high cholesterol, impaired fasting glucose and/or impaired glucose tolerance, minor polypharmacy, use of heart/circulation drugs, and cholesterol measurements after screening predicted the prescription of lipid-lowering drugs for patients at high risk of CVD. For patients with CVD, male gender, high cholesterol and use of heart/circulation drugs predicted the prescription of lipid-lowering drugs. No general practice characteristics were associated with different prescription habits. CONCLUSION: There is a gap between the recommended lipid-lowering drug therapy and current practice, with a substantial under-treatment and a considerable delay in the first prescription of lipid-lowering drugs.
OBJECTIVE: To describe the management of dyslipidaemia in patients with high risk of cardiovascular disease (CVD) and patients with a history of CVD identified by screening for diabetes in general practice in Denmark, concentrating on prescription of lipid-lowering drugs. Moreover, to analyse predicting factors for starting lipid-lowering drugs related to patient and general practice characteristics. DESIGN: Population-based cross-sectional study with follow-up. SETTING: A total of 139 general practices from three of five Danish regions, totalling 216 GPs. SUBJECTS: The study population comprised 4986 patients with a high risk of CVD and dyslipidaemia and 764 patients with a history of CVD and dyslipidaemia out of a population of 16 572 patients who completed screening for diabetes but were cleared for diabetes in the ADDITION study. RESULTS: Of patients with a high risk of CVD and dyslipidaemia not receiving lipid-lowering drugs at the time of screening (n = 4823), 20% started lipid-lowering therapy within the follow-up period (median 2.1 years). This percentage was 45% (n = 536) for patients with CVD and dyslipidaemia (median follow-up period 1.6 years). Age over 50, high cholesterol, impaired fasting glucose and/or impaired glucose tolerance, minor polypharmacy, use of heart/circulation drugs, and cholesterol measurements after screening predicted the prescription of lipid-lowering drugs for patients at high risk of CVD. For patients with CVD, male gender, high cholesterol and use of heart/circulation drugs predicted the prescription of lipid-lowering drugs. No general practice characteristics were associated with different prescription habits. CONCLUSION: There is a gap between the recommended lipid-lowering drug therapy and current practice, with a substantial under-treatment and a considerable delay in the first prescription of lipid-lowering drugs.
Authors: Edward J Mills; Beth Rachlis; Ping Wu; Philip J Devereaux; Paul Arora; Dan Perri Journal: J Am Coll Cardiol Date: 2008-11-25 Impact factor: 24.094
Authors: Charlotte Gry Harmsen; Ivar Sønbø Kristiansen; Pia Veldt Larsen; Jørgen Nexøe; Henrik Støvring; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Dorte Ejg Jarbøl Journal: Br J Gen Pract Date: 2014-04 Impact factor: 5.386
Authors: Lise Graversen; Bo Christensen; Knut Borch-Johnsen; Torsten Lauritzen; Annelli Sandbaek Journal: Scand J Prim Health Care Date: 2011-12 Impact factor: 2.581
Authors: Pia Kirkegaard; Adrian G K Edwards; Bo Hansen; Mette D Hansen; Morten S A Jensen; Torsten Lauritzen; Mette B Risoer; Janus L Thomsen Journal: BMC Fam Pract Date: 2010-09-22 Impact factor: 2.497
Authors: Petra G van Peet; Jacobijn Gussekloo; Wendy P J den Elzen; Jeanet W Blom; Margot W M de Waal; Wouter de Ruijter Journal: Scand J Prim Health Care Date: 2015 Impact factor: 2.581
Authors: Heike U Krämer; Elke Raum; Gernot Rüter; Ben Schöttker; Dietrich Rothenbacher; Thomas Rosemann; Joachim Szecsenyi; Hermann Brenner Journal: Cardiovasc Diabetol Date: 2012-07-27 Impact factor: 9.951
Authors: Benedicte Lind Barfoed; Dorte Ejg Jarbøl; Maja Skov Paulsen; Palle Mark Christensen; Peder Andreas Halvorsen; Jesper Bo Nielsen; Jens Søndergaard Journal: Int J Family Med Date: 2015-10-08